Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379329 | 1.00 | CRBN (0.47) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24411108 | 1.00 | CRBN (0.47) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL5958850 | 0.86 | CRBN (0.50) | CRBNDDB1ALDH1A1IKZF3 | |
| SCHEMBL5958867 | 0.84 | DDB1 (0.52) | CRBNDDB1IKZF3 | |
| SCHEMBL29546964 | 0.84 | DDB1 (0.50) | CRBNDDB1 | |
| SCHEMBL24379209 | 0.84 | DDB1 (0.50) | CRBNDDB1 | |
| SCHEMBL24379351 | 0.83 | CRBN (0.40) | CRBNDDB1ALDH1A1CYP1A2TSHR | |
| SCHEMBL5958898 | 0.83 | CRBN (0.49) | CRBNDDB1ALDH1A1TSHR | |
| SCHEMBL24411109 | 0.83 | CYP19A1 (0.41) | CRBNDDB1 | |
| SCHEMBL5958909 | 0.83 | DDB1 (0.39) | CRBNDDB1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1710242-A1 | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha levels | CELGENE CORPORATION (US) | 2006-10-11 | — | — | EP | claimed |
| EP-1308444-B1 | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha Levels | CELGENE CORP (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-05-12 | — | — | US | claimed |
| EP-1308444-A1 | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha Levels | CELGENE CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| EP-1062214-B1 | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFA LEVELS | CELGENE CORP (US) | 2003-03-05 | — | — | EP | claimed |
| US-5955476-A | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION (US) | 1999-09-21 | — | — | US | claimed |
| US-5874448-A | DRUGS FOR REDUCING THE LEVEL OF TUMOR NECROSIS FACTOR, INCREASING ADENOSINE-3',5'CYCLIC MONOPHOSPHATE, INHIBITING PHOSPHODIESTERASE; TREATING BONE DISORDER, INFECTIONS, CANCER, IMMUNE DISEASE | CELGENE CORPORATION (US) | 1999-02-23 | — | — | US | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| EP-4658317-A1 | PROGRAMMABLE DNA PROTEOLYSIS TARGET CHIMERAS AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4598582-A1 | PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025136129-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET PROTEIN KINASE C | CAPTOR THERAPEUTICS S.A. (PL) | 2025-06-26 | — | — | WO | disclosed |
| EP-1062214-A1 | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFA LEVELS | CELGENE CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5955476-A | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5955476-A | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1999046258-A1 | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFα LEVELS | CELGENE CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046258-A1 | SUBSTITUTED 2-(2,6-DIOXO-3-FLUOROPIPERIDIN-3-YL)-ISOINDOLINES AND THEIR USE TO REDUCE TNFα LEVELS | CELGENE CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5874448-A | DRUGS FOR REDUCING THE LEVEL OF TUMOR NECROSIS FACTOR, INCREASING ADENOSINE-3',5'CYCLIC MONOPHOSPHATE, INHIBITING PHOSPHODIESTERASE; TREATING BONE DISORDER, INFECTIONS, CANCER, IMMUNE DISEASE | CELGENE CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5874448-A | DRUGS FOR REDUCING THE LEVEL OF TUMOR NECROSIS FACTOR, INCREASING ADENOSINE-3',5'CYCLIC MONOPHOSPHATE, INHIBITING PHOSPHODIESTERASE; TREATING BONE DISORDER, INFECTIONS, CANCER, IMMUNE DISEASE | CELGENE CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CA13, CA12, CA14 | CRBN 1923/4885DDB1 993/4885ALDH1A1 1232/4885 |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | XIAP, MDM2, SARS1 | CRBN 4/4885DDB1 429/4885ALDH1A1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.